Glimepiride 2mg + Metformin 500mg SR Bilayered Tablets are a dedicated solid oral formulation that combines the APIs Glimepiride 2mg and Metformin 500mg into a Bilayered tablet dosage form. The formulation is established by pharmaceutical-controlled manufacturing processes where the two APIs are processed with active excipients and release controlling ingredients into defined formulation layers. For companies seeking to add an advanced oral pharmaceutical into their portfolio, a professionally organized PCD Pharma Franchise range may include:
The structured bilayered formulation relies upon a defined, structured manufacturing process where the two layers are each developed and processed with their own specific formulation control strategy. The sustained-release component needs particular control over the formulation constituents, compression pattern and dissolution behavior to create a consistent release profile.
Manufacturing begins with the qualification of pharmaceutical-grade APIs from the manufacturers in the form of each active dose. Each lot of API is tested to a set of agreed specifications before release to manufacture. Testing may include tests such as: identification, assay, purity, moisture content, particle size, and others.
The formulation is developed by accounting for the quality control attributes of the two APIs to facilitate integrating them into the correct layer of the finished dosage form. The 2mg dose of Glimepiride and 500mg dose of Metformin are dispensed into the blending operation with controls to minimize batch-to-batch variation.
The Metformin layer may be combined with a suitable sustained-release matrix or other release modifier technology, depending on the final formulation structure. The Glimepiride layer is formulated independently with suitable excipients to achieve the necessary processing and pharmaceutical characteristics.
Selection of excipients can support processing functions such as powder flow, binding, compression, disintegration, lubrication, and controlled release. Compatibility testing can also be performed to confirm the final formulation design to create a stable pharmaceutical composition.
Bilayer tablet manufacturing involves the preparation of two, separate finished formulation blends or granulations, which are subsequently compressed sequentially to form finished tablets. Each layer is compressed independently before the formulated granulation from each layer is introduced into a dedicated bilayer compression unit.
During compression, the first layer is accurately filled into the die and subjected to a defined compression pattern. The second layer is then introduced and compressed to form a finished bilayered tablet with the first layer.
Process parameters can include the individual layer weight, compression force, precompression force, tablet thickness, compression speed and dwell time. These are set up during product development and controlled throughout production.
The Metformin layer of the bilayer tablet can include a sustained-release matrix or other release-modulating technology depending on the final designed product. Once compressed, this layer is subjected to dissolution testing to define the release profile.
In particular, interlayer bonding is an important quality attribute for a bilayer tablet, and appropriate compression parameters will help to ensure the finished tablets are less likely to exhibit problems such as layer separation, cracking, capping or deformation while also maintaining the required bilayered structure.
The two formulation layers are prepared separately using controlled manufacturing procedures. Depending on the exact process, steps such as granulation, drying, milling, sizing, blending and lubrication can be included as part of either formulation step before compression.
The blending operation controls the uniform distribution of API through the finished formulation layer, with controls to optimize mixing time and order of ingredient addition. During compression, in-process controls include weights, hardness, thickness, friability, visual observation and layer integrity. Sampling at defined intervals can flag minor variations in the process.
The relatively low dose of Glimepiride compared to Metformin requires accurate dispensing and suitable blending steps to ensure batch-to-batch consistency of formulation units. Sample collection can include representative sampling of process material during formulation blending steps, and systematic transfer of materials.
The compression equipment can include checks on tablet weight, pressure control, punch quality, and compression speed. Equipment is regularly calibrated, cleaned, and maintained to minimize variation. Batch records can document the equipment number, material quantities and batches, yields and process parameters.
Quality control testing of the API and the finished formulation includes testing for the two active ingredients, as well as the finished formulation. Finished-product testing can include: identification, assay, related substances, dissolution, product uniformity, weight variation, weight and thickness, friability, and visual inspection.
Dissolution testing has particular relevance for the sustained release matrix in the Metformin layer. Samples can be withdrawn at pre-specified test time points to establish the release profile. This can be compared to product specification.
Uniformity testing checks the individual content of each API in the finished unit of the product. Assay and related substances methods can be validated or verified for the intended purpose.
Quality assurance procedures include checks on the raw-material test results, batch processing data, test laboratory data, equipment calibration, and packaging information prior to product release.
Stability evaluation can determine whether the finished bilayer formulation maintains its integrity and physical parameters in storage. Storage conditions and testing time points should be set up in accordance with the applicable stability protocol.
Stability monitoring can include observations of physical appearance, related substances, assay, and the dissolution profile of the formulation. A stable dissolution profile should demonstrate that the sustained-release property is maintained.
Suitable packaging material can be selected to optimize protection of the product, taking into account the requirements of the stability testing. The packaging structure should be compatible with the stability criteria, and should provide the necessary environmental barrier properties.
Within the PCD Pharma Franchise segment, a total solution including API qualification, bilayer formulation development, technology compression, dissolution evaluation, stability monitoring, and packaging implementation can be delivered to professionally organized franchise partners.
Glimepiride 2mg + Metformin 500mg SR Bilayered Tablets with formulation, bilayer technology, manufacturing, quality control, stability and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech